Wednesday, July 31, 2024 12:02:47 PM
"Donnenamab 3brain bleed deaths directly related 2drug" So give me the pill at bedtime. I'll sleep better and won't wake up with dizziness. And I darned sure won't get Brain Bleed.
Nidan if the company were lying to us the law suits would instantly abound. Vs some dizzy babe on Seeking Alpo trying to make a few nickels and get followers. I'll take the companies word for it every time.
Hosai I see nothing to stop us from approval by EMA. Yes the time to get it all processed through their system. I have waited 9 years no big deal to wait another few months. And YES If Anavex had screening like the MAB's did our results would be even better than they were with little screening.
Hoskuld ADL is irrelevant, as has been stated many times. The focus on this alone reveals the bias of the author. The tau, AB, brain volume, and cognition data were outstandingly good. 2-73 should be part of any AD treatment regimen - and I think it will be. Cure? No. New standard of care? Yes. And if something else comes along then it will still be part of the regimen.
I am 1000% in agreement with your statement!!
williamssc Anavex first to approval has some worried. Leaders get the arrows.
and the MAB's get the Arrows. You wouldn't get me to take any of them.
🏁🏁 The Checkered Flag is in sight GO FOR IT NOW. 🏁🏁
John k9uwa
Nidan if the company were lying to us the law suits would instantly abound. Vs some dizzy babe on Seeking Alpo trying to make a few nickels and get followers. I'll take the companies word for it every time.
Hosai I see nothing to stop us from approval by EMA. Yes the time to get it all processed through their system. I have waited 9 years no big deal to wait another few months. And YES If Anavex had screening like the MAB's did our results would be even better than they were with little screening.
Hoskuld ADL is irrelevant, as has been stated many times. The focus on this alone reveals the bias of the author. The tau, AB, brain volume, and cognition data were outstandingly good. 2-73 should be part of any AD treatment regimen - and I think it will be. Cure? No. New standard of care? Yes. And if something else comes along then it will still be part of the regimen.
I am 1000% in agreement with your statement!!
williamssc Anavex first to approval has some worried. Leaders get the arrows.
and the MAB's get the Arrows. You wouldn't get me to take any of them.
🏁🏁 The Checkered Flag is in sight GO FOR IT NOW. 🏁🏁
John k9uwa
Bullish
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
